Characterization of Genetically Altered, Interleukin 2-Independent Natural Killer Cell Lines Suitable for Adoptive Cellular Immunotherapy
- 20 May 1999
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 10 (8) , 1359-1373
- https://doi.org/10.1089/10430349950018030
Abstract
NK-92 is a highly cytotoxic natural killer (NK) tumor cell line that possesses properties that make it an excellent candidate for adoptive cellular immunotherapy. However, the cytotoxicity of NK cells is dependent on cytokines such as interleukin 2 (IL-2). Although NK-92 cells maintain cytotoxicity for a time after withdrawal of IL-2, clinical use will probably require prolonged treatment with fully activated cells to eliminate disease effectively. The ability to support cytotoxic cells with exogenously administered IL-2 is limited by associated toxicity. Therefore, we describe the transfection of the IL-2-dependent NK-92 cell line with human IL-2 (hIL2) cDNA by particle-mediated gene transfer to create two IL-2-independent variants, NK-92MI and NK-92 CI, and describe their characterization and comparison with parental cells. Both variants were shown to contain, express, and synthesize the hIL-2 cDNA. IL-2 synthesis was higher in NK-92MI cells compared with NK-92CI cells, with no expression in parental cells. Functionally, the cytotoxicity of all three cell lines was similar and coincubation with IL-2-independent variants did not affect hematopoietic progenitor cells. NK92MI and NK-92 CI cells were more radiosensitive than NK-92 cells, with proliferation inhibited at lower radiation doses and increased morality and decreased cytotoxicity compared with parental cells. Data presented here show that we have created by particle-mediated gene transfer two IL-2-independent variants of NK-92 that are identical to parental cells in virtually all respects, including high cytotoxic activity. The nonviral transfection of these cells makes them suitable for clinical applications. These IL-2-independent cells should allow prolonged treatment with fully active natural killer cells without the need for exogenous IL-2 support.Keywords
This publication has 29 references indexed in Scilit:
- Evaluation of Recommendations for Replication-Competent Retrovirus Testing Associated with Use of Retroviral VectorsHuman Gene Therapy, 1997
- Structure and expression of two highly related genes encoding SCM‐1/human lymphotactinFEBS Letters, 1996
- Generation of activated natural killer (A‐NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl‐positive targetsBritish Journal of Haematology, 1996
- Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinial relevanceImmunology Today, 1995
- Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2JNCI Journal of the National Cancer Institute, 1994
- Establishment and Characterization of a Human Leukemic Cell Line (SR-91) with Features Suggestive of Early Hematopoietic Progenitor Cell OriginLeukemia & Lymphoma, 1994
- Action of natural killer cells and macrophages in cancerCurrent Opinion in Immunology, 1993
- Prospective Randomized Trial of High-Dose Interleukin-2 Alone or in Conjunction With Lymphokine-Activated Killer Cells for the Treatment of Patients With Advanced CancerJNCI Journal of the National Cancer Institute, 1993
- Interleukin-6 does not support interleukin-2 induced generation of human lymphokine-activated killer cellsCancer Immunology, Immunotherapy, 1991
- Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases.The Journal of Experimental Medicine, 1991